Skip to content

PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | The NEW ENGLAND JOURNAL Of MEDICINE

Authors: Andrea Cercek, M.D., Melissa Lumish, M.D. https://orcid.org/0000-0003-4173-5567, Jenna Sinopoli, N.P., Jill Weiss, B.A., Jinru Shia, M.D., MichelleLamendola-Essel, D.H.Sc., Imane H. El Dika, M.D., and Luis A. Diaz, Jr., M.D.

BACKGROUND

Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is caused by a deficiency in mismatch repair. Because mismatch repair–deficient colorectal cancer is responsive to programmed death 1 (PD-1) blockade in the context of metastatic disease, it was hypothesized that checkpoint blockade could be effective in patients with mismatch repair–deficient, locally advanced rectal cancer.

METHODS

We initiated a prospective phase 2 study in which single-agent dostarlimab, an anti–PD-1 monoclonal antibody, was administered every 3 weeks for 6 months in patients with mismatch repair–deficient stage II or III rectal adenocarcinoma. This treatment was to be followed by standard chemoradiotherapy and surgery. Patients who had a clinical complete response after completion of dostarlimab therapy would proceed without chemoradiotherapy and surgery. The primary end points are sustained clinical complete response 12 months after completion of dostarlimab therapy or pathological complete response after completion of dostarlimab therapy with or without chemoradiotherapy and overall response to neoadjuvant dostarlimab therapy with or without chemoradiotherapy.
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

RESULTS

A total of 12 patients have completed treatment with dostarlimab and have undergone at least 6 months of follow-up. All 12 patients (100%; 95% confidence interval, 74 to 100) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging, 18F-fluorodeoxyglucose–positron-emission tomography, endoscopic evaluation, digital rectal examination, or biopsy. At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months). No adverse events of grade 3 or higher have been reported.

CONCLUSIONS

Mismatch repair–deficient, locally advanced rectal cancer was highly sensitive to single-agent PD-1 blockade. Longer follow-up is needed to assess the duration of response. (Funded by the Simon and Eve Colin Foundation and others; ClinicalTrials.gov number, NCT04165772.)
Locally advanced rectal cancer is typically managed with multimodal therapy, including chemotherapy, radiation, and surgery. Current evidence supports a strategy involving the use of neoadjuvant therapy, in which induction chemotherapy with a fluoropyrimidine in combination with oxaliplatin is followed by chemoradiotherapy and then surgery.1-3 This approach results in a pathological complete response in up to a quarter of patients, but it is associated with marked complications and toxic effects — including bowel, urinary, and sexual dysfunction; infertility; and altered quality of life — in a substantial proportion of patients.4-6 In patients undergoing surgery, resection of the rectum is life-altering and often warrants a permanent diverting colostomy.6,7 Owing to the complications of surgery and the high frequency of pathological complete response, interest in organ-sparing nonoperative management is increasing. The use of clinical complete response that is achieved with neoadjuvant treatment as a surrogate for pathological complete response provides patients with a nonoperative option that results in a survival benefit that is similar to that in patients undergoing surgical resection.8-11
Approximately 5 to 10% of rectal adenocarcinomas are mismatch-repair deficient, and these tumors have been shown to respond poorly to standard chemotherapy regimens, including neoadjuvant chemotherapy in locally advanced rectal cancer.12-14 Immune checkpoint blockade alone has been shown to be highly effective as first-line treatment for patients with mismatch repair–deficient metastatic colorectal cancer, as well as for patients with treatment-refractory disease, with objective response rates of 33 to 55%, clinically significant durability of response, and prolonged overall survival.15-17
On the basis of the benefits seen in the context of metastatic disease, we hypothesized that single-agent programmed death 1 (PD-1) blockade alone might be beneficial in mismatch repair–deficient, locally advanced rectal cancer. To test this hypothesis, we initiated a phase 2 study to investigate the overall response and frequency of sustained clinical complete response to neoadjuvant treatment with dostarlimab, a PD-1 inhibitor, in this patient population.

Skip The Scoop | Seek Understanding

FDA ordered Johnson & Johnson to throw out 60 million COVID-19 vaccine doses

Show Me

For Kids, Benefits of COVID Vaccine ‘Don’t Outweigh Risks,’ Experts Tell FDA

Show Me

Bannon’s War Room | Morning Edition Hour 1 | Recorded June 11, 2021 | Video: 48 Minutes 47 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 2 | Recorded June 11, 2021 | Video: 47 Minutes 47 Seconds

Show Me

Bannon’s War Room | Evening Edition | Recorded June 11, 2021 | Video: 48 Minutes 58 Seconds

Show Me

The Secret Meeting that shaped the Natural Origins Narrative | Truth Over News

Show Me

Judicial Watch Files Two New Federal FOIA Lawsuits for Information on COVID and Wuhan Institute of Virology

Show Me

FLASHBACK, May 2020, Democrats Announce Intent to Use ISIS Level Propaganda Against Trump on COVID Messaging

Show Me

Rand Paul: Fauci’s ‘One-Size-Fits-All’ Approach on Vaccine Based on ‘Regular People Aren’t Smart Enough’ to Make Decisions

Show Me

Of Course He Did | ‘Let Us Try To Do This Next Weekend’: Emails Show Fauci Planning To Dine With Friend During Lockdowns

Show Me

J&J CEO: People Will Need COVID Vaccine With Annual Flu Shot for Next Several Years + More

Show Me

Sen. John Kennedy tells Fauci to ‘cut the crap’ after doc lashes out at critics

Show Me

Fauci: To Attack Me Is to Attack Science

Show Me

June 10, 2021 | Nightly News Rebroadcast | Video: 46 Minutes 50 Seconds

Show Me

A Look Back, May 19, 2021 Interview | Dr. Peter McCullough Discusses The Dangers Of The Novel COVID Vaccine And It’s Roll Out | Dr. McCullough: Internist, Cardiologist, Epidemiologist, and Professor of Medicine at Texas A & M College of Medicine, Dallas, TX | Video: 1 Hour 45 Minutes 28 Seconds

Show Me

America’s Energy Gift to Dictators

Show Me

Nearly 800 Reports of Heart Inflammation After COVID-19 Vaccination in US

Show Me

Commentary: ‘Pristine’ Biden Ballots That Looked Xeroxed and Why a Judge Has Georgia Vote Fraud on His Mind

Show Me

Covid-19 origins, the Wuhan lab, US funding, and vaccine connection

Show Me

Native American contractors’ letter seeks end to ‘destructive and unlawful protests’ over Line 3 pipeline

Show Me

When the Bison Return, Will Their Habitat Rebound?

Show Me

How a Questionable Drug Turned into a Goldmine at Taxpayers’ Expense

Show Me

Is NYC Going to Get Schooled Under a New Mayor? 

Show Me

Air Force: Disorientation, faulty GPS caused deadly F-16 crash in Michigan

Show Me

Iranian warships believed to be transporting arms reach Atlantic on route to Venezuela

Show Me

Senator Elizabeth Warren (aka Pocahontas) Shares Link to Stolen Data on Taxes Paid by the Super Wealthy to Push Taxing the Rich

Show Me

Bannon’s War Room | Morning Edition Hour 1 | Recorded June 10, 2021 | Video: 48 Minutes 29 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 2 | Recorded June 10, 2021 | Video: 48 Minutes 05 Seconds

Show Me

Bannon’s War Room | Evening Edition | Recorded June 10, 2021 | Video: 48 Minutes 59 Seconds

Show Me

Media Matters Retracts After Falsely Claiming Republican Politician Went On ‘White Nationalist, Pro-Hitler Outlet’

Show Me

Study: No COVID-19 Reinfections in Unvaccinated Group

Show Me

How a lenient NYC judge left a reputed gangbanger free to allegedly kill an innocent dad

Show Me

Court reinstates teacher suspended for speaking out against proposed transgender policy

Show Me

Study Shows Hydroxychloroquine and Azithromycin Greatly Improved COVID Survival Rate for Ventilated Patients

Show Me

Keystone pipeline nixed after Biden stands firm on permit

Show Me

Newsom and California lawmakers approved to receive pay raise amid improving economy

Show Me

Ex-Tennessee governor tied to contract hit on Hoffa pal, federal witness

Show Me

Social media CEO considers suing political blogger over Jan. 6 Capitol riot story

Show Me

June 9, 2021 | Nightly News Rebroadcast | Video: 43 Minutes 01 Seconds

Show Me

WATCH: Fauci Claims to “Have No Idea” About His Own, Documented E-Mails with Mark Zuckerberg.

Show Me